The company said, "ELZONRIS clinical data from its ongoing Phase 2 clinical trial in patients with CMML were presented at the 2019 American Society of
Clinical Oncology annual meeting in Chicago, Illinois and at the 24th Congress of the European Hematology Association in Amsterdam, Netherlands.
The submission is based on results from the Phase 3 ARCHES trial presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in February and published in The Journal of
Clinical Oncology. The study evaluated the efficacy and safety of XTANDI plus androgen deprivation therapy (ADT) versus ADT plus placebo in men with mHSPC.
Summary: Growing prevalence of cancer has underpinned the demand for the
clinical oncology next-generation sequencing market
The submission is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking abstract at the annual meeting of the American Society of
Clinical Oncology (ASCO) in June.
As per details, Saadia Qadir, a student of Daanish School (Girls) Hasilpur participated in the presentation held by Pakistan Society of
Clinical Oncology on the project of anti-skin care lotion.
She is a member of the American Society of
Clinical Oncology, American Society of Hematology, American Association of Cancer Research and America Society of Clinical Investigation.
To the Editor.--We highly appreciated the recent publication on the update of human epidermal growth factor receptor 2 (HER2) testing guideline for breast cancer by the American Society of
Clinical Oncology (ASCO) and the College of American Pathologists (CAP) in Journal of
Clinical Oncology.
He expressed these views at the 23rd annual Cancer Congress Seminar 2019 organised by the Pakistan Society of
Clinical Oncology at a local hotel of Peshawar.
Currently, Dr Basse is a member of the European Society of Medical Oncology as well as the American Society of
Clinical Oncology.
He joins Infinity from Agios Pharmaceuticals Inc, where he played a pivotal role in the development of the company's oncology programs, including two novel
clinical oncology medicines, IDHIFA and TIBSOVO, as vice president and head of Clinical Development.